Neurological Adverse Events Related to Immune Checkpoint Inhibitors: A Practical Review - PubMed
Source : https://pubmed.ncbi.nlm.nih.gov/38675461/
The increasing use of immune checkpoint inhibitors (ICI) in cancer therapy has brought attention to their associated neurotoxicities, termed neurological immune-related adverse events (n-irAEs). Despite their relatively rare incidence, n-irAEs...
This review provides an overview of neurological immune-related adverse events (n-irAEs) caused by immune checkpoint inhibitors, emphasizing recognition, management, and the importance of multidisciplinary approaches and severity grading.
Ravulizumab for adults with generalized myasthenia gravis: a plain language summary of three studies - PubMed
Source : https://pubmed.ncbi.nlm.nih.gov/39387235/
Ravulizumab can be considered as a treatment option for adults with gMG who are appropriately protected against meningococcal infection before starting treatment. The drug, administered every 8 weeks, improves muscle...
Ravulizumab improves muscle strength and daily function in adults with generalized myasthenia gravis (gMG), is well-tolerated, and effective with 8-week dosing, sustaining benefits for up to 60 weeks.
Telitacicept in combination with B-cell depletion therapy in MuSK antibody-positive myasthenia gravis: a case report and literature review - PubMed
Source : https://pubmed.ncbi.nlm.nih.gov/39624088/
Muscle-specific kinase (MuSK) myasthenia gravis (MG) is relatively rare and has a higher incidence of myasthenic crisis compared with other subtypes. However, there is still a lack of effective treatment...
A 70-year-old MuSK MG patient stabilized on telitacicept combined with anti-CD20 therapy. This novel regimen, alongside a review of 14 reported cases, highlights potential treatment advancements for refractory MuSK MG.
Time to response with ravulizumab, a long-acting terminal complement inhibitor, in adults with anti-acetylcholine receptor antibody-positive generalized myasthenia gravis - PubMed
Source : https://pubmed.ncbi.nlm.nih.gov/39373062/
The median times to MCID with ravulizumab treatment in patients with AChR Ab+ gMG were ~2 weeks and ~4 weeks based on MCID MG-ADL and QMG total score reductions, respectively.
The CHAMPION MG study showed ravulizumab reduced Myasthenia Gravis symptoms in AChR Ab+ gMG patients, with median response times of ~2 weeks for MG-ADL and ~4 weeks for QMG score reductions.
Risk-Benefit Analysis of Novel Treatments for Patients with Generalized Myasthenia Gravis - PubMed
Source : https://pubmed.ncbi.nlm.nih.gov/39470879/
FcRn inhibitors and complement inhibitors assessed in this study all demonstrated clinical benefit in terms of NNT as well as an acceptable safety profile in terms of NNH. Within the...
This network meta-analysis compared treatments for anti-AChR Ab+ generalized myasthenia gravis, finding efgartigimod IV to have the lowest NNT, NNH, and CPIO, demonstrating a favorable benefit-risk profile and better economic value.